Pradaxa has warnings for excessive bleeding. Pradaxa Helpline is concerned about Pradaxa and the elderly
The Pradaxa Helpline Has Pradaxa Lawyers to Help You
LONDON | Fri May 25, 2012 6:07am EDT
(Reuters) – Doctors and patients should be given clearer guidance on how to avoid bleeding risks when using Boehringer Ingelheim's new stroke prevention pill Pradaxa, European regulators said on Friday.
The European Medicines Agency said data continued to confirm the positive benefit-risk balance of the anticoagulant medicine, despite cases of fatal bleeding, but advice on the risks should be strengthened.
Pradaxa is the first in a new class of medicines aimed at replacing the old and problematic drug warfarin. It is designed for use after hip and knee surgery and to prevent strokes in patients with atrial fibrillation, a form of irregular heartbeat common among the elderly.
Rival drugs include Xarelto, from Bayer and Johnson & Johnson, and Eliquis, from Bristol-Myers Squibb and Pfizer.
Pradaxa is an anticoagulant. Anticoagulants effect the clotting time of the blood. Pradaxa is described as a prescription blood-thinning medicine used to reduce the risk of stroke and blood clots in people with atrial fibrillation not caused by a heart valve problem. With atrial fibrillation, part of the heart does not beat the way it should. This can cause blood clots to form, increasing your risk of a stroke. Pradaxa lowers the chance of blood clots forming in your body. There is a chnce of excessive bleeding on Pradaxa that can be fatal.